Geron Corp
F:GON
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Geron Corp
F:GON
|
US |
|
A
|
Abb Ltd
XBER:ABJA
|
CH |
|
H
|
H & R Block Inc
DUS:HRB
|
US |
|
M
|
MasTec Inc
F:MY8
|
US |
|
A
|
Asahi Intecc Co Ltd
F:6XT
|
JP |
|
Lifetime Brands Inc
NASDAQ:LCUT
|
US |
|
L
|
L'Oreal SA
XETRA:LOR
|
FR |
|
M
|
Marsh & McLennan Companies Inc
XETRA:MSN
|
US |
|
F
|
Ford Motor Co
XHAM:FMC1
|
US |
|
A
|
American Express Co
XMUN:AEC1
|
US |
|
M
|
Manulife Financial Corp
XBER:MLU
|
CA |
|
Annaly Capital Management Inc
F:AAYA
|
US |
|
T
|
Tokyo Electron Ltd
F:TKY
|
JP |
|
Banco Bilbao Vizcaya Argentaria SA
LSE:BVA
|
ES |
|
Seven & i Holdings Co Ltd
TSE:3382
|
JP |
|
B
|
BriQ Properties REIC
ATHEX:BRIQ
|
GR |
Geron Corp
Geron Corp is a biotechnology company focused on developing cancer and blood-disorder medicines, especially imetelstat, a drug designed to block telomerase. Its main goal is to turn this drug into approved treatments for patients with diseases such as certain bone marrow disorders and blood cancers. In plain terms, Geron is a drug developer, not a broad pharmaceutical company with a large portfolio of marketed products. The company makes money by advancing its drug candidates through testing, regulatory review, and, if successful, commercialization. That can include selling a drug itself, partnering with larger drug makers, or licensing rights in some cases. For now, its business is still centered on research, clinical development, and building a market for its lead therapy. What makes Geron different is that it is highly focused on one core scientific approach rather than many products. That can make the company more dependent on the success of a single medicine, but it also gives investors a clear story: if imetelstat works as planned, Geron can become a specialist supplier of a targeted therapy for patients with limited treatment options.
Geron Corp is a biotechnology company focused on developing cancer and blood-disorder medicines, especially imetelstat, a drug designed to block telomerase. Its main goal is to turn this drug into approved treatments for patients with diseases such as certain bone marrow disorders and blood cancers. In plain terms, Geron is a drug developer, not a broad pharmaceutical company with a large portfolio of marketed products.
The company makes money by advancing its drug candidates through testing, regulatory review, and, if successful, commercialization. That can include selling a drug itself, partnering with larger drug makers, or licensing rights in some cases. For now, its business is still centered on research, clinical development, and building a market for its lead therapy.
What makes Geron different is that it is highly focused on one core scientific approach rather than many products. That can make the company more dependent on the success of a single medicine, but it also gives investors a clear story: if imetelstat works as planned, Geron can become a specialist supplier of a targeted therapy for patients with limited treatment options.
Revenue: RYTELO net revenue was $51.8 million in Q1 2026, up 31% year over year and 8% quarter over quarter, and management said the company remains on track to meet full-year revenue guidance.
Outlook: Geron reiterated 2026 guidance for RYTELO net revenue of $220 million to $240 million and total operating expenses of $230 million to $240 million, with more revenue growth expected in the back half of the year.
Demand: U.S. demand rose 6% quarter over quarter, prescribing accounts grew about 12%, and the company expanded to approximately 1,450 accounts as it pushed harder into second-line lower-risk MDS.
Europe: Management said it is exploring several options for launching RYTELO in Europe, including partnerships and newer commercial models, and expects to update investors before year-end.
Financial discipline: Total operating expenses were $50.4 million, down about 9% year over year, and cash ended the quarter at about $341 million after bonus, severance, and supply-chain investments.
Pipeline: The Phase III IMpactMF interim analysis is still expected in the second half of 2026, with overall survival as the primary endpoint and an earlier positive result described as upside.
